Missing pieces in the Parkinson's disease puzzle

@article{Obeso2010MissingPI,
  title={Missing pieces in the Parkinson's disease puzzle},
  author={Jose A. Obeso and Maria C. Rodriguez-Oroz and Christopher G Goetz and Concepci{\'o} Mar{\'i}n and Jeffrey H. Kordower and Manuel Rodriguez and Etienne C. Hirsch and Matthew J Farrer and Anthony H. V. Schapira and Glenda M. Halliday},
  journal={Nature Medicine},
  year={2010},
  volume={16},
  pages={653-661}
}
Parkinson's disease is a neurodegenerative process characterized by numerous motor and nonmotor clinical manifestations for which effective, mechanism-based treatments remain elusive. Here we discuss a series of critical issues that we think researchers need to address to stand a better chance of solving the different challenges posed by this pathology. 
Epidemiology of Parkinson's disease.
TLDR
Some of the methodological challenges involved in assessing the descriptive, prognostic and etiological epidemiological studies of PD are discussed, and their main findings are summarized. Expand
Molecular Targets for Improvement of Parkinson's Disease Therapy
TLDR
An overview of molecular targets whose attack can contribute to improve the therapy of Parkinson’s disease and putative targets for new therapeutical measures are presented. Expand
Parkinson disease: Parkinson disease clinical subtypes and their implications
TLDR
A new study supports distinct clinical subtypes of Parkinson disease that could have implications for understanding the etiology of this condition. Expand
[Future drug targets for Parkinson's disease].
  • E. Hirsch
  • Medicine
  • Bulletin de l'Academie nationale de medecine
  • 2012
TLDR
This review examines the mechanisms of neuronal degeneration in Parkinson's disease, new targets for neuroprotection, and the mechanisms causing symptoms resistant to current treatments. Expand
Biomarkers of Parkinson's disease
TLDR
This chapter focuses on the progress of several promising biomarkers for Parkinson's disease, which hold the potential to aid in the clinical management of the disease. Expand
Animal models of neurodegenerative diseases.
TLDR
The purpose of this review is to present the main animal models for AD, PD, and Huntington's disease. Expand
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease
  • E. Hirsch, D. Standaert
  • Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2020
TLDR
10 unanswered questions related to neuroinflammatory processes in Parkinson's disease are reviewed with the goal of stimulating research in the field and accelerating the clinical development of neuroprotective therapies based on anti‐inflammatory strategies. Expand
Etiology and pathogenesis of Parkinson's disease
  • A. Schapira, P. Jenner
  • Biology, Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2011
TLDR
Focusing on those events that characterize Parkinson's disease, namely, mitochondrial dysfunction and Lewy body formation, may be the key to further advancing the understanding of pathogenesis and to taking these mechanisms forward as a means of defining targets for neuroprotection. Expand
Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease
Parkinson's disease (PD) is one of the most common neurodegenerative disorders that seriously impair the life quality and survival of patients. Herein, we aim to investigate the neuroprotective rolesExpand
Can Parkinson's disease pathology be propagated from one neuron to another?
TLDR
The staging (according to Braak) of Parkinson pathology and the concept describing the disease progression from one region of the brain to the other are discussed and how α-synuclein might be responsible for the spread of the disease are highlighted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 126 REFERENCES
What causes cell death in Parkinson's disease?
TLDR
Many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration are reviewed. Expand
Molecular basis of Parkinson's disease.
TLDR
This work discusses what has been learnt in the study of these genes and how these genes may contribute to the pathogenesis of Parkinson's disease through different molecular pathways, and considers how these pathways might converge to lead to the onset of Parkinson’s disease. Expand
Genetics of Parkinson disease: paradigm shifts and future prospects
  • M. Farrer
  • Biology, Medicine
  • Nature Reviews Genetics
  • 2006
TLDR
Genetic insights provide the rationale for new strategies for prevention or therapy, and have led to animal models of disease in which these strategies can be tested. Expand
Is Parkinson's disease a prion disorder?
TLDR
It is demonstrated that nerve cells that overexpress tagged α-synuclein can transmit the protein to neural stem cells in both in vitro and in vivo models, which could explain the remarkable finding that human embryonic dopamine nerve cells implanted into the striatum of patients with Parkinson's disease develop PD pathology with loss of dopamine markers and classic Lewy bodies. Expand
Research in motion: the enigma of Parkinson's disease pathology spread
TLDR
The paper discusses the possible underlying mechanisms and their implications for how pathology spreads in Parkinson's disease and demonstrates that grafted healthy neurons can gradually develop the same pathology as host neurons in the diseased brains. Expand
Neurobiology and treatment of Parkinson's disease.
  • A. Schapira
  • Psychology, Medicine
  • Trends in pharmacological sciences
  • 2009
TLDR
Progress in the management of PD has continued, particularly in timing of drug initiation and the sequence and combinations in which drugs are used to improve long-term outcome and reduce drug-induced complications, and particular progress has been made in the field of neuroprotection. Expand
The genetics of Parkinson's syndromes: a critical review.
TLDR
It is argued that this designation of PARK loci is misleading and that if the authors seek to understand the pathogenesis, they should study the genetics of Lewy body diseases: these include not only idiopathic Parkinson's disease, but also such disparate syndromes as Hallevorden-Spatz disease and Niemann-Pick Type C. Expand
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years
Postmortem analysis of five subjects with Parkinson's disease 9–14 years after transplantation of fetal midbrain cell suspensions revealed surviving grafts that included dopamine and serotoninExpand
α-Synuclein Locus Triplication Causes Parkinson's Disease
Mutations in the α-synuclein gene ( SNCA ) in the Contursi kindred ([ 1 ][1]) implicated this gene in Parkinson's disease (PD). Subsequently, α-synuclein was identified as the major component of LewyExpand
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Fourteen years after transplantation into the striatum of an individual with Parkinson's disease, grafted nigral neurons were found to have Lewy body–like inclusions that stained positively forExpand
...
1
2
3
4
5
...